1) Powerful demographic, sociological, and technological forces are driving a shift from paying pharmaceutical companies per prescription filled to paying based on the performance and outcomes of the drugs for different patients.
2) Large volumes of health data will be aggregated and analyzed to determine how individual patients respond to drugs and develop patient segment profiles to prescribe drugs more accurately. This will give insights to develop new treatments.
3) Countries have established agencies to evaluate cost-effectiveness of new therapies, and reimbursement is increasingly contingent on clinical proof of effectiveness for specific patients. This will transform reimbursement from a fixed price to one based on outcomes for individual patients and patient segments.
Make DNA data actionable - Festival of Genomics London 2018Omar Fogliadini
Consumers are looking for more control over their own health and healthcare, and with the advent of affordable genetic testing there are new avenues for personalised treatment and precision medicine.
As consumer tests come to the fore and patients arrive at their doctor appointments brandishing their own genetic data and full of questions and opinions. Concerns still remain that patients – and not a few physicians – don't always understand what the genetic results mean and just what to do about them. But as consumers get more comfortable with those companies' offerings, the visits with their doctors are often getting more complex.
With the increased use of the Internet for medical information, consumers have become medical consumers not just patients This has created a change in the doctor/patient relationship as individuals become more knowledgeable about their own health and want more control over their personal information and treatment decisions. Physicians, meanwhile, are concerned about giving patients too much access to information they may not properly understand. Even many doctors aren't well-trained in the clinical implications of genetics and genomics.
The CMO’s Generation Genome report is focused on the need for the UK to maintain its presence as a world leader in genomic medicine. It presented a vision of genomics being integrated into the NHS within the next 5 years.
The “vast majority” of NHS doctors are “not up to speed” with modern genetic techniques that can transform patients’ chances.
GENOMIC INTELLIGENCE
Suisse Life Science specialiSes in making DNA data useful for population health management.
Using our flagship Scienceof[DNA]f(x) technology, Suisse Life Science Group can provide you with an evidence-based lifestyle behavioural medicine dynamic system based on the associated genetic variants supported by literature citations for health, wellness or chronic diseases, and customised around your needs.
What used to take weeks of painstaking manual curation can now be completed in days.
PERSONALISED HEALTH TECHNOLOGY FOR GENOMIC COMPANIES OR CUSTOM APPLICATIONS
We help companies by providing a comprehensive nutritional, metabolic and lifestyle analysis and management program that includes nutrition intake and lifestyle monitoring, followed by a personalised nutritional, chronic disease prevention and sport recommendations, tailored for the user, informed on their biomarkers but updated - in real-time - with life data from consumer devices (smartphones, wearables…).
Ready-to-market technology.
Ask for a demo at info@suisselifescience.com
Thomas Willkens-El impacto de las ciencias ómicas en la medicina, la nutrició...Fundación Ramón Areces
El 29 de marzo de 2016 celebramos un Simposio Internacional sobre el 'Impacto de las ciencias ómicas en la medicina, nutrición y biotecnología'. Organizado por la Fundación Ramón Areces en colaboración con la Real Academia Nacional de Medicina y BioEuroLatina, abordó cómo un mejor conocimiento del genoma humano está permitiendo notables avances hacia una medicina de precisión.
Webinar: Defeating Superbugs: Hospitals on the Front Lines Modern Healthcare
About the Webinar: Defeating Superbugs: Hospitals on the Front Lines
http://www.modernhealthcare.com/article/20140917/INFO/309179926
Hospitals across the country are facing a grim reality in which some of the most deadly healthcare-associated infections they encounter are untreatable with first- or even second-line antibiotics. These “superbugs” affect at least 2 million Americans each year and lead to 23,000 deaths. And their threat is growing, public health officials warn. This editorial webinar and “Defeating Superbugs” white paper will explore the steps providers must take to ramp up surveillance efforts, promote appropriate antibiotic use and control outbreaks. Our panel of experts will share their organizations' experiences as well as proven strategies for success.
Registration for this webinar includes Modern Healthcare's “Defeating Superbugs” white paper, with proven tips and strategies for promoting appropriate antibiotic use, improving infection surveillance, identifying drug-resistant infections and dealing with outbreaks.
KEY TAKEAWAYS
- Best practices for effective antimicrobial stewardship
- Real-world examples of effective interventions, including universal rapid testing for drug-resistant MRSA
- Tips for engaging senior leadership
- Aggressive strategies for controlling outbreaks
PANELISTS
Lance Peterson
Director of the Clinical Microbiology and Infectious Disease Research Division
NorthShore University HealthSystem, Evanston, Ill.
Anurag Malani
Medical Director for the Infection Prevention and Antimicrobial Stewardship Programs
St. Joseph Mercy Hospital, Ann Arbor, Mich.
Robert Weinstein
Chief Medical Officer for Population Health
Chairman of the Department of Medicine, Cook County Health and Hospitals System; Professor, Rush University Medical Center, Chicago
MODERATOR
Maureen McKinney
Editorial Programs Manager
Modern Healthcare
Towards Digitally Enabled Genomic Medicine: the Patient of The FutureLarry Smarr
12.02.22
Invited Speaker
Hacking Life
TTI/Vanguard Conference
Title: Towards Digitally Enabled Genomic Medicine: the Patient of The Future
San Jose, CA
Make DNA data actionable - Festival of Genomics London 2018Omar Fogliadini
Consumers are looking for more control over their own health and healthcare, and with the advent of affordable genetic testing there are new avenues for personalised treatment and precision medicine.
As consumer tests come to the fore and patients arrive at their doctor appointments brandishing their own genetic data and full of questions and opinions. Concerns still remain that patients – and not a few physicians – don't always understand what the genetic results mean and just what to do about them. But as consumers get more comfortable with those companies' offerings, the visits with their doctors are often getting more complex.
With the increased use of the Internet for medical information, consumers have become medical consumers not just patients This has created a change in the doctor/patient relationship as individuals become more knowledgeable about their own health and want more control over their personal information and treatment decisions. Physicians, meanwhile, are concerned about giving patients too much access to information they may not properly understand. Even many doctors aren't well-trained in the clinical implications of genetics and genomics.
The CMO’s Generation Genome report is focused on the need for the UK to maintain its presence as a world leader in genomic medicine. It presented a vision of genomics being integrated into the NHS within the next 5 years.
The “vast majority” of NHS doctors are “not up to speed” with modern genetic techniques that can transform patients’ chances.
GENOMIC INTELLIGENCE
Suisse Life Science specialiSes in making DNA data useful for population health management.
Using our flagship Scienceof[DNA]f(x) technology, Suisse Life Science Group can provide you with an evidence-based lifestyle behavioural medicine dynamic system based on the associated genetic variants supported by literature citations for health, wellness or chronic diseases, and customised around your needs.
What used to take weeks of painstaking manual curation can now be completed in days.
PERSONALISED HEALTH TECHNOLOGY FOR GENOMIC COMPANIES OR CUSTOM APPLICATIONS
We help companies by providing a comprehensive nutritional, metabolic and lifestyle analysis and management program that includes nutrition intake and lifestyle monitoring, followed by a personalised nutritional, chronic disease prevention and sport recommendations, tailored for the user, informed on their biomarkers but updated - in real-time - with life data from consumer devices (smartphones, wearables…).
Ready-to-market technology.
Ask for a demo at info@suisselifescience.com
Thomas Willkens-El impacto de las ciencias ómicas en la medicina, la nutrició...Fundación Ramón Areces
El 29 de marzo de 2016 celebramos un Simposio Internacional sobre el 'Impacto de las ciencias ómicas en la medicina, nutrición y biotecnología'. Organizado por la Fundación Ramón Areces en colaboración con la Real Academia Nacional de Medicina y BioEuroLatina, abordó cómo un mejor conocimiento del genoma humano está permitiendo notables avances hacia una medicina de precisión.
Webinar: Defeating Superbugs: Hospitals on the Front Lines Modern Healthcare
About the Webinar: Defeating Superbugs: Hospitals on the Front Lines
http://www.modernhealthcare.com/article/20140917/INFO/309179926
Hospitals across the country are facing a grim reality in which some of the most deadly healthcare-associated infections they encounter are untreatable with first- or even second-line antibiotics. These “superbugs” affect at least 2 million Americans each year and lead to 23,000 deaths. And their threat is growing, public health officials warn. This editorial webinar and “Defeating Superbugs” white paper will explore the steps providers must take to ramp up surveillance efforts, promote appropriate antibiotic use and control outbreaks. Our panel of experts will share their organizations' experiences as well as proven strategies for success.
Registration for this webinar includes Modern Healthcare's “Defeating Superbugs” white paper, with proven tips and strategies for promoting appropriate antibiotic use, improving infection surveillance, identifying drug-resistant infections and dealing with outbreaks.
KEY TAKEAWAYS
- Best practices for effective antimicrobial stewardship
- Real-world examples of effective interventions, including universal rapid testing for drug-resistant MRSA
- Tips for engaging senior leadership
- Aggressive strategies for controlling outbreaks
PANELISTS
Lance Peterson
Director of the Clinical Microbiology and Infectious Disease Research Division
NorthShore University HealthSystem, Evanston, Ill.
Anurag Malani
Medical Director for the Infection Prevention and Antimicrobial Stewardship Programs
St. Joseph Mercy Hospital, Ann Arbor, Mich.
Robert Weinstein
Chief Medical Officer for Population Health
Chairman of the Department of Medicine, Cook County Health and Hospitals System; Professor, Rush University Medical Center, Chicago
MODERATOR
Maureen McKinney
Editorial Programs Manager
Modern Healthcare
Towards Digitally Enabled Genomic Medicine: the Patient of The FutureLarry Smarr
12.02.22
Invited Speaker
Hacking Life
TTI/Vanguard Conference
Title: Towards Digitally Enabled Genomic Medicine: the Patient of The Future
San Jose, CA
Is the increasing availability of automated image analysis a possibility to strengthen the application of diffusion-MRI as a biometric parameter, and to enhance the future of image biobanks? Or is this evolution threatening the position of radiologists as medical doctors. Is a redefinition of radiologist as computer technicians inevitable?
Hinf6230 Technology Assessment Gideon Presentation Abel SunilAbel Gebreyesus
The presentation is a review of the Global Infectious Disease and Epidemiology Online Network (GIDEON) tool. It is a web-based Infectious Disease Diagnosis computer program that constructs a differential diagnosis [DD], ranked in order of percent probability based on specific clinical data entered by user in the field of Geographic Medicine. The primary aim of GIDEON is to help physicians diagnose infectious diseases originating from or within any country of the world at the point-of-care. Other than as a clinical decision support system providing up-to-date evidence-based resource, the tool is a vast reservoir of country-specific information on epidemiology, anti-infective drugs and vaccines and a resource for teaching in the fields of Tropical & Infectious Diseases, Epidemiology and Microbiology.
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
Enabling community and patient centred care, pop up uni, 11am, 3 september 2015NHS England
Expo is the most significant annual health and social care event in the calendar, uniting more NHS and care leaders, commissioners, clinicians, voluntary sector partners, innovators and media than any other health and care event.
Expo 15 returned to Manchester and was hosted once again by NHS England. Around 5000 people a day from health and care, the voluntary sector, local government, and industry joined together at Manchester Central Convention Centre for two packed days of speakers, workshops, exhibitions and professional development.
This year, Expo was more relevant and engaging than ever before, happening within the first 100 days of the new Government, and almost 12 months after the publication of the NHS Five Year Forward View. It was also a great opportunity to check on and learn from the progress of Greater Manchester as the area prepares to take over a £6 billion devolved health and social care budget, pledging to integrate hospital, community, primary and social care and vastly improve health and well-being.
More information is available online: www.expo.nhs.uk
In times of duress and difficulty, it is imperative for leaders to rise from the shadows and steer the people into a future of possibility and hope. Leadership is not always assigned, rather it is clarified in times of trial. As John Kenneth Galbraith said, leadership is the confrontation of the major anxiety of their people in their time.
- Jake Dahge
We can aid decision making from the pre-clinical to the clinical setting, supporting line of sight to the clinic, by identifying and translating crucial biomarker approaches into the real world.
Sepsis is one of the top causes of inpatient mortality and rapid detection presents numerous challenges. In March, 2016, an interdisciplinary team consisting of top clinicians, data scientists and machine learning experts at a large academic medical center (AMC) embarked on an innovation pilot to develop a novel machine learning model to detect sepsis. A computable sepsis definition and deep learning model were developed using a curated dataset capturing over 43,000 inpatient admissions between October 1, 2014 and December 31, 2015. Ten computable sepsis definitions were compared and our clinicians agreed on the following: >= 2 SIRS criteria, blood culture order, and end organ damage. This sepsis phenotype identified patients early in the hospital course: 38% of cases occur an average of 1.3 hours after presentation to the ED and 42% of cases occur an average of 15 hours after hospital admission. At 4 hours prior to sepsis, the best deep learning model generated 1.4 false alarms per true alarm at a sensitivity of 80%, compared to 3.2 false alarms per true alarm for National Early Warning System (NEWS).
Purpose
Sepsis Watch detects sepsis early, guides completion of appropriate treatment, and supports front-line providers with minimal interruption of clinical workflows. Key Performance Indicators include emergency department (ED) length of stay, hospital length of stay, inpatient mortality, intensive care unit requirement, and time to antibiotics for patients who develop sepsis.
Description
The core technology components of Sepsis Watch are web services to extract electronic health record (EHR) data in real-time, a data pipeline to normalize features, a computable sepsis definition, a deep learning sepsis prediction model, a web application (Figure 1), an automated report that calculates KPI performance, and a model input and output monitoring tool. A suite of education, training, communication, and workflow materials were also prepared with nurse educators and are hosted on an intranet training site. After a three-month silent period, Sepsis Watch was deployed in the ED of the 1,000 bed flagship hospital on November 5, 2018.
Conclusions
Sepsis Watch is the first deployment of deep learning model in real-time to detect sepsis integrated with an EHR. The tool is used by Rapid Response Team (RRT) nurses to provide proactive support to ED providers to identify and manage sepsis. A six-month clinical trial will be completed in May 2019 to rigorously assess the clinical and operational impact of the program.
Pharma’s future has never looked more promising – or more ominous.
Major scientific, technological and socioeconomic changes will revive
the industry’s fortunes in another decade, but capitalising on these
trends will entail making crucial decisions first
Design of a Clinical Decision Support System Framework for the Diagnosis and ...Editor IJCATR
This paper proposes an adaptive framework for a Knowledge Based Intelligent Clinical Decision Support System for the
prediction of hepatitis B which is one of the most deadly viral infections that has a monumental effect on the health of people afflicted
with it and has for long remained a perennial health problem affecting a significant number of people the world over. In the framework
the patient information is fed into the system; the Knowledge base stores all the information to be used by the Clinical Decision
Support System and the classification/prediction algorithm chosen after a thorough evaluation of relevant classification algorithms for
this work is the C4.5 Decision Tree Algorithm with its percentage of correctly classified instances given as 61.0734%; it searches the
Knowledge base recursively and matches the patient information with the pertinent rules that suit each case and thereafter gives the
most precise prediction as to whether the patient is prone to hepatitis B or not. This approach to the prediction of hepatitis B provides a
very potent solution to the problem of determining if a person has the likelihood of developing this dreaded illness or is almost not
susceptible to the ailment.
It's no secret that the healthcare system needs some work. In fact, it's not really a system at all. It's confusing, it's difficult to navigate, and it's too expensive. When you combine that with some of the demographic trends that you see in our country — the population is getting older, we're experiencing more chronic disease — it gets even more complicated and more expensive. And consumer expectations are changing dramatically as well. So, this creates an opportunity for an organization like ours to lead this digital transformation.
Steve Nelson, CEO
UnitedHealthcare
Immuron Limited (NASDAQ: IMRN; ASX: IMC), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered polyclonal antibodies
for the treatment of inflammatory mediated and infectious diseases. Immuron’s technology
platform utilizes highly specific vaccines for the generation of hyperimmune antibody-rich
bovine colostrum, providing a means of antimicrobial therapy without the drawbacks of
antibiotics to treat gut-mediated diseases. The Company currently markets Travelan®, which
is a listed medicine on the Australian Register for Therapeutic Goods, in Australia to reduce
the risk of travelers’ diarrhea (TD). In Canada, Travelan® is a licensed natural health
product and is indicated to reduce the risk of travelers’ diarrhea. In the U.S. Travelan® is
sold as a dietary supplement for digestive-tract protection. Immuron recently announced
plans to pursue clinical development of its lead drug candidate, IMM-124E, through a formal
FDA registration pathway as a drug to specifically prevent TD. Immuron’s second clinicalstage asset, IMM-529, targets Clostridium difficile infections (CDI), and is presently in a
clinical trial in CDI patients.
Malcolm Pradhan on Pathology in Clincial Decision Support and the role of Dee...Cirdan
Pathology testing plays an important role in the management of complex patients. Pathology laboratories continue to improve the speed and accuracy of result reporting, however the clinical management of pathology remains challenging: there is well documented variation in ordering practices, slow take-up of order sets, and up to 40% of pathology tests are not reviewed by clinical staff. The inefficient clinical utilization of pathology is a significant cost, both directly and through increased patient length of stay in hospital.
One of the established ways to improve health care delivery is integrated clinical decision support (CDS). Malcolm discusses how the effective implementation of CDS for pathology results can improve clinical productivity and patient safety. Looking further ahead the challenge for health care is to develop models of care that better tailor decisions to the needs of individual patients, and technology is required to achieve this goal. He gives a high level overview of recent advances in technology, such as big data analytics and deep learning, that will be vital in creating a sustainable health care system.
Artificial Intelligence and Machine Learning will have a profound effect in transforming healthcare and bridging the historical gap of information asymmetry between the healthcare ecosystem and people
Is the increasing availability of automated image analysis a possibility to strengthen the application of diffusion-MRI as a biometric parameter, and to enhance the future of image biobanks? Or is this evolution threatening the position of radiologists as medical doctors. Is a redefinition of radiologist as computer technicians inevitable?
Hinf6230 Technology Assessment Gideon Presentation Abel SunilAbel Gebreyesus
The presentation is a review of the Global Infectious Disease and Epidemiology Online Network (GIDEON) tool. It is a web-based Infectious Disease Diagnosis computer program that constructs a differential diagnosis [DD], ranked in order of percent probability based on specific clinical data entered by user in the field of Geographic Medicine. The primary aim of GIDEON is to help physicians diagnose infectious diseases originating from or within any country of the world at the point-of-care. Other than as a clinical decision support system providing up-to-date evidence-based resource, the tool is a vast reservoir of country-specific information on epidemiology, anti-infective drugs and vaccines and a resource for teaching in the fields of Tropical & Infectious Diseases, Epidemiology and Microbiology.
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
Enabling community and patient centred care, pop up uni, 11am, 3 september 2015NHS England
Expo is the most significant annual health and social care event in the calendar, uniting more NHS and care leaders, commissioners, clinicians, voluntary sector partners, innovators and media than any other health and care event.
Expo 15 returned to Manchester and was hosted once again by NHS England. Around 5000 people a day from health and care, the voluntary sector, local government, and industry joined together at Manchester Central Convention Centre for two packed days of speakers, workshops, exhibitions and professional development.
This year, Expo was more relevant and engaging than ever before, happening within the first 100 days of the new Government, and almost 12 months after the publication of the NHS Five Year Forward View. It was also a great opportunity to check on and learn from the progress of Greater Manchester as the area prepares to take over a £6 billion devolved health and social care budget, pledging to integrate hospital, community, primary and social care and vastly improve health and well-being.
More information is available online: www.expo.nhs.uk
In times of duress and difficulty, it is imperative for leaders to rise from the shadows and steer the people into a future of possibility and hope. Leadership is not always assigned, rather it is clarified in times of trial. As John Kenneth Galbraith said, leadership is the confrontation of the major anxiety of their people in their time.
- Jake Dahge
We can aid decision making from the pre-clinical to the clinical setting, supporting line of sight to the clinic, by identifying and translating crucial biomarker approaches into the real world.
Sepsis is one of the top causes of inpatient mortality and rapid detection presents numerous challenges. In March, 2016, an interdisciplinary team consisting of top clinicians, data scientists and machine learning experts at a large academic medical center (AMC) embarked on an innovation pilot to develop a novel machine learning model to detect sepsis. A computable sepsis definition and deep learning model were developed using a curated dataset capturing over 43,000 inpatient admissions between October 1, 2014 and December 31, 2015. Ten computable sepsis definitions were compared and our clinicians agreed on the following: >= 2 SIRS criteria, blood culture order, and end organ damage. This sepsis phenotype identified patients early in the hospital course: 38% of cases occur an average of 1.3 hours after presentation to the ED and 42% of cases occur an average of 15 hours after hospital admission. At 4 hours prior to sepsis, the best deep learning model generated 1.4 false alarms per true alarm at a sensitivity of 80%, compared to 3.2 false alarms per true alarm for National Early Warning System (NEWS).
Purpose
Sepsis Watch detects sepsis early, guides completion of appropriate treatment, and supports front-line providers with minimal interruption of clinical workflows. Key Performance Indicators include emergency department (ED) length of stay, hospital length of stay, inpatient mortality, intensive care unit requirement, and time to antibiotics for patients who develop sepsis.
Description
The core technology components of Sepsis Watch are web services to extract electronic health record (EHR) data in real-time, a data pipeline to normalize features, a computable sepsis definition, a deep learning sepsis prediction model, a web application (Figure 1), an automated report that calculates KPI performance, and a model input and output monitoring tool. A suite of education, training, communication, and workflow materials were also prepared with nurse educators and are hosted on an intranet training site. After a three-month silent period, Sepsis Watch was deployed in the ED of the 1,000 bed flagship hospital on November 5, 2018.
Conclusions
Sepsis Watch is the first deployment of deep learning model in real-time to detect sepsis integrated with an EHR. The tool is used by Rapid Response Team (RRT) nurses to provide proactive support to ED providers to identify and manage sepsis. A six-month clinical trial will be completed in May 2019 to rigorously assess the clinical and operational impact of the program.
Pharma’s future has never looked more promising – or more ominous.
Major scientific, technological and socioeconomic changes will revive
the industry’s fortunes in another decade, but capitalising on these
trends will entail making crucial decisions first
Design of a Clinical Decision Support System Framework for the Diagnosis and ...Editor IJCATR
This paper proposes an adaptive framework for a Knowledge Based Intelligent Clinical Decision Support System for the
prediction of hepatitis B which is one of the most deadly viral infections that has a monumental effect on the health of people afflicted
with it and has for long remained a perennial health problem affecting a significant number of people the world over. In the framework
the patient information is fed into the system; the Knowledge base stores all the information to be used by the Clinical Decision
Support System and the classification/prediction algorithm chosen after a thorough evaluation of relevant classification algorithms for
this work is the C4.5 Decision Tree Algorithm with its percentage of correctly classified instances given as 61.0734%; it searches the
Knowledge base recursively and matches the patient information with the pertinent rules that suit each case and thereafter gives the
most precise prediction as to whether the patient is prone to hepatitis B or not. This approach to the prediction of hepatitis B provides a
very potent solution to the problem of determining if a person has the likelihood of developing this dreaded illness or is almost not
susceptible to the ailment.
It's no secret that the healthcare system needs some work. In fact, it's not really a system at all. It's confusing, it's difficult to navigate, and it's too expensive. When you combine that with some of the demographic trends that you see in our country — the population is getting older, we're experiencing more chronic disease — it gets even more complicated and more expensive. And consumer expectations are changing dramatically as well. So, this creates an opportunity for an organization like ours to lead this digital transformation.
Steve Nelson, CEO
UnitedHealthcare
Immuron Limited (NASDAQ: IMRN; ASX: IMC), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered polyclonal antibodies
for the treatment of inflammatory mediated and infectious diseases. Immuron’s technology
platform utilizes highly specific vaccines for the generation of hyperimmune antibody-rich
bovine colostrum, providing a means of antimicrobial therapy without the drawbacks of
antibiotics to treat gut-mediated diseases. The Company currently markets Travelan®, which
is a listed medicine on the Australian Register for Therapeutic Goods, in Australia to reduce
the risk of travelers’ diarrhea (TD). In Canada, Travelan® is a licensed natural health
product and is indicated to reduce the risk of travelers’ diarrhea. In the U.S. Travelan® is
sold as a dietary supplement for digestive-tract protection. Immuron recently announced
plans to pursue clinical development of its lead drug candidate, IMM-124E, through a formal
FDA registration pathway as a drug to specifically prevent TD. Immuron’s second clinicalstage asset, IMM-529, targets Clostridium difficile infections (CDI), and is presently in a
clinical trial in CDI patients.
Malcolm Pradhan on Pathology in Clincial Decision Support and the role of Dee...Cirdan
Pathology testing plays an important role in the management of complex patients. Pathology laboratories continue to improve the speed and accuracy of result reporting, however the clinical management of pathology remains challenging: there is well documented variation in ordering practices, slow take-up of order sets, and up to 40% of pathology tests are not reviewed by clinical staff. The inefficient clinical utilization of pathology is a significant cost, both directly and through increased patient length of stay in hospital.
One of the established ways to improve health care delivery is integrated clinical decision support (CDS). Malcolm discusses how the effective implementation of CDS for pathology results can improve clinical productivity and patient safety. Looking further ahead the challenge for health care is to develop models of care that better tailor decisions to the needs of individual patients, and technology is required to achieve this goal. He gives a high level overview of recent advances in technology, such as big data analytics and deep learning, that will be vital in creating a sustainable health care system.
Artificial Intelligence and Machine Learning will have a profound effect in transforming healthcare and bridging the historical gap of information asymmetry between the healthcare ecosystem and people
As we understand more about the human body and how it functions and degrades, biotechnology will progress. This is only the beginning, but when new technology and procedures become accessible, certain themes will start to develop in biopharma trends.
Precision medicine is an emerging strategy that considers individual variability in genes, environment, and lifestyle to diagnose, treat, forecast, and prevent disease. As regulatory health authorities begin to develop clearer regulatory pathways in precision medicine, industries must prepare to swiftly adopt to any regulatory changes. This white paper aims to provide a broad overview on the following key topics in precision medicine:
1. Genomics and Pharmacogenetics
2. Precision Medicine vs Personalized Medicine
3. Foundation of Precision Medicine as A Treatment Tool
4. Examples of Precision Medicine as A Treatment, Predictive, and Preventative Tool
5. Precision Medicine and Cancer
6. Challenges, Next Step & Opportunities in Precision Medicine
7. Regulatory insight on Precision medicine
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...Covance
Despite the growing availability of approved gene therapies, decision-makers face significant challenges when evaluating pricing and reimbursement of these novel therapeutics. From determining cost-benefit ratios, setting out patient access criteria and designing reimbursement plans, this white paper explores some of the complex aspects of value assessment for gene therapies, and discusses results from a survey of key decision-makers across Germany, Sweden and the UK responsible for making pricing and reimbursement decisions.
Companies, organizations, and research institutes that are committed to bettering the lives of living organisms fall under the umbrella term known as the life sciences industry. Pharmaceuticals, biotechnology, environmental sciences, biomedicine, nutraceuticals, neurology, cell biology, biophysics, and a lot of other subfields might be classified as some of the different subfields that fall under the umbrella of the life sciences business.
Making DNA data actionable. Genomic intelligence for good health without pill...Omar Fogliadini
THE SMART WAY TO TAKE CHARGE OF YOUR HEALTH
Get so many insights from your DNA that no doctor could ever tell you
Hear what your body has to say and live better - by your own rules
A healthy lifestyle is especially hard to do alone. Now you've a Personal Health Coach that customizes your advice before you slip from being healthy into the early stage of an illness.
A scientific approach to wellness.
Try now.
PERSONALIZED HEALTH
PERSONALIZED NUTRITION
BRAIN POWER PERFORMANCE
Our digital health programs give you access to behavioral coaching via web or mobile, night or day - like having the world’s leading experts on call but tailored to you and your lifestyle.
Suisse Life Science is a biological big data analytics company that has developed a knowledge-discovery platform to extract cause-effect relationships directly from genetic interpretation – and at scale – linking them to lifestyle data from consumer devices in real time to provide actionable recommendations.
Suisse Life Science specializes in making DNA data useful for population health management.
Now, it’s easier than ever to develop innovative consumer products enhanced and personalized through the power of DNA
We help companies and institutions by providing a comprehensive nutritional, metabolic and lifestyle analysis and management program that includes nutrition intake and lifestyle monitoring, followed by a personalized nutritional, chronic disease prevention and fitness recommendations, tailored for the user, informed on their biomarkers and updated - in real-time - with life data from consumer devices (smartphones, wearables…).
Consumer are looking for more control over their health, and with the advent of affordable genetic testing there are new avenues for personalized treatment and precision medicine.
Concerns still remain that patients – and not a few physicians – don't always understand what the genetic results mean and just what to do about them. Even many doctors aren't well-trained in the clinical implications of genetics and genomics. Without burdening yourself, you can now deliver personalized treatments and behavioral health programs with a mobile AI assistant that provides genetic counseling, tailored to the user, and supports your customers 24/7.
What used to take weeks of painstaking manual curation can now be completed in days.
Our technology is ready-to-market and it can be customized according to your specific needs across the aging and age-related disease prevention and management.
We have all-in-one solutions including our proprietary genetic panels - or we can integrate existing inflows of genetic data.
Twenty-first century technologies will create significant opportunities and challenges for all healthcare stakeholders. Pharmacovigilance (PV) too is in transition, with new sources of medical information and methods for its analysis that will transform today's largely reactive system into proactive benefit-risk management for all medication users.
When the Human Genome Project was declared complete back in 2003, there were high expectations set for genomic medicine. However, it has taken over a decade to begin moving from vision to reality. Today, the number of success stories remains relatively small, but they do stretch across the healthcare ecosystem, incorporating the prediction of drug responses, the diagnosis of diseases and the identification of targeted therapies. Stakeholders ranging from patients, healthcare providers and payers, researchers, diagnostic companies, policy-makers, life sciences businesses and governments now believe genomic medicine to be a potential game-changer
The Pharma 2020 series
The Pharmaceutical industry's long successful strategy of placing big bets on a few molecules, promoting them heavily and turning them into blockbusters worked well for many years, but its R&D productivity has now plummeted and the environment’s changing. PwC believes that seven major trends are reshaping the marketplace:
Source of info:
http://www.pwc.com/gx/en/pharma-life-sciences/pharma2020/index.jhtml#
Accpac to QuickBooks Conversion Navigating the Transition with Online Account...PaulBryant58
This article provides a comprehensive guide on how to
effectively manage the convert Accpac to QuickBooks , with a particular focus on utilizing online accounting services to streamline the process.
The world of search engine optimization (SEO) is buzzing with discussions after Google confirmed that around 2,500 leaked internal documents related to its Search feature are indeed authentic. The revelation has sparked significant concerns within the SEO community. The leaked documents were initially reported by SEO experts Rand Fishkin and Mike King, igniting widespread analysis and discourse. For More Info:- https://news.arihantwebtech.com/search-disrupted-googles-leaked-documents-rock-the-seo-world/
As a business owner in Delaware, staying on top of your tax obligations is paramount, especially with the annual deadline for Delaware Franchise Tax looming on March 1. One such obligation is the annual Delaware Franchise Tax, which serves as a crucial requirement for maintaining your company’s legal standing within the state. While the prospect of handling tax matters may seem daunting, rest assured that the process can be straightforward with the right guidance. In this comprehensive guide, we’ll walk you through the steps of filing your Delaware Franchise Tax and provide insights to help you navigate the process effectively.
What is the TDS Return Filing Due Date for FY 2024-25.pdfseoforlegalpillers
It is crucial for the taxpayers to understand about the TDS Return Filing Due Date, so that they can fulfill your TDS obligations efficiently. Taxpayers can avoid penalties by sticking to the deadlines and by accurate filing of TDS. Timely filing of TDS will make sure about the availability of tax credits. You can also seek the professional guidance of experts like Legal Pillers for timely filing of the TDS Return.
Affordable Stationery Printing Services in Jaipur | Navpack n PrintNavpack & Print
Looking for professional printing services in Jaipur? Navpack n Print offers high-quality and affordable stationery printing for all your business needs. Stand out with custom stationery designs and fast turnaround times. Contact us today for a quote!
What are the main advantages of using HR recruiter services.pdfHumanResourceDimensi1
HR recruiter services offer top talents to companies according to their specific needs. They handle all recruitment tasks from job posting to onboarding and help companies concentrate on their business growth. With their expertise and years of experience, they streamline the hiring process and save time and resources for the company.
Enterprise Excellence is Inclusive Excellence.pdfKaiNexus
Enterprise excellence and inclusive excellence are closely linked, and real-world challenges have shown that both are essential to the success of any organization. To achieve enterprise excellence, organizations must focus on improving their operations and processes while creating an inclusive environment that engages everyone. In this interactive session, the facilitator will highlight commonly established business practices and how they limit our ability to engage everyone every day. More importantly, though, participants will likely gain increased awareness of what we can do differently to maximize enterprise excellence through deliberate inclusion.
What is Enterprise Excellence?
Enterprise Excellence is a holistic approach that's aimed at achieving world-class performance across all aspects of the organization.
What might I learn?
A way to engage all in creating Inclusive Excellence. Lessons from the US military and their parallels to the story of Harry Potter. How belt systems and CI teams can destroy inclusive practices. How leadership language invites people to the party. There are three things leaders can do to engage everyone every day: maximizing psychological safety to create environments where folks learn, contribute, and challenge the status quo.
Who might benefit? Anyone and everyone leading folks from the shop floor to top floor.
Dr. William Harvey is a seasoned Operations Leader with extensive experience in chemical processing, manufacturing, and operations management. At Michelman, he currently oversees multiple sites, leading teams in strategic planning and coaching/practicing continuous improvement. William is set to start his eighth year of teaching at the University of Cincinnati where he teaches marketing, finance, and management. William holds various certifications in change management, quality, leadership, operational excellence, team building, and DiSC, among others.
Taurus Zodiac Sign_ Personality Traits and Sign Dates.pptxmy Pandit
Explore the world of the Taurus zodiac sign. Learn about their stability, determination, and appreciation for beauty. Discover how Taureans' grounded nature and hardworking mindset define their unique personality.
Cracking the Workplace Discipline Code Main.pptxWorkforce Group
Cultivating and maintaining discipline within teams is a critical differentiator for successful organisations.
Forward-thinking leaders and business managers understand the impact that discipline has on organisational success. A disciplined workforce operates with clarity, focus, and a shared understanding of expectations, ultimately driving better results, optimising productivity, and facilitating seamless collaboration.
Although discipline is not a one-size-fits-all approach, it can help create a work environment that encourages personal growth and accountability rather than solely relying on punitive measures.
In this deck, you will learn the significance of workplace discipline for organisational success. You’ll also learn
• Four (4) workplace discipline methods you should consider
• The best and most practical approach to implementing workplace discipline.
• Three (3) key tips to maintain a disciplined workplace.
Memorandum Of Association Constitution of Company.pptseri bangash
www.seribangash.com
A Memorandum of Association (MOA) is a legal document that outlines the fundamental principles and objectives upon which a company operates. It serves as the company's charter or constitution and defines the scope of its activities. Here's a detailed note on the MOA:
Contents of Memorandum of Association:
Name Clause: This clause states the name of the company, which should end with words like "Limited" or "Ltd." for a public limited company and "Private Limited" or "Pvt. Ltd." for a private limited company.
https://seribangash.com/article-of-association-is-legal-doc-of-company/
Registered Office Clause: It specifies the location where the company's registered office is situated. This office is where all official communications and notices are sent.
Objective Clause: This clause delineates the main objectives for which the company is formed. It's important to define these objectives clearly, as the company cannot undertake activities beyond those mentioned in this clause.
www.seribangash.com
Liability Clause: It outlines the extent of liability of the company's members. In the case of companies limited by shares, the liability of members is limited to the amount unpaid on their shares. For companies limited by guarantee, members' liability is limited to the amount they undertake to contribute if the company is wound up.
https://seribangash.com/promotors-is-person-conceived-formation-company/
Capital Clause: This clause specifies the authorized capital of the company, i.e., the maximum amount of share capital the company is authorized to issue. It also mentions the division of this capital into shares and their respective nominal value.
Association Clause: It simply states that the subscribers wish to form a company and agree to become members of it, in accordance with the terms of the MOA.
Importance of Memorandum of Association:
Legal Requirement: The MOA is a legal requirement for the formation of a company. It must be filed with the Registrar of Companies during the incorporation process.
Constitutional Document: It serves as the company's constitutional document, defining its scope, powers, and limitations.
Protection of Members: It protects the interests of the company's members by clearly defining the objectives and limiting their liability.
External Communication: It provides clarity to external parties, such as investors, creditors, and regulatory authorities, regarding the company's objectives and powers.
https://seribangash.com/difference-public-and-private-company-law/
Binding Authority: The company and its members are bound by the provisions of the MOA. Any action taken beyond its scope may be considered ultra vires (beyond the powers) of the company and therefore void.
Amendment of MOA:
While the MOA lays down the company's fundamental principles, it is not entirely immutable. It can be amended, but only under specific circumstances and in compliance with legal procedures. Amendments typically require shareholder